DK3160978T3 - Gemcitabin-prodrugs - Google Patents

Gemcitabin-prodrugs Download PDF

Info

Publication number
DK3160978T3
DK3160978T3 DK15733497.0T DK15733497T DK3160978T3 DK 3160978 T3 DK3160978 T3 DK 3160978T3 DK 15733497 T DK15733497 T DK 15733497T DK 3160978 T3 DK3160978 T3 DK 3160978T3
Authority
DK
Denmark
Prior art keywords
gemcitabin
products
gemcitabin products
Prior art date
Application number
DK15733497.0T
Other languages
English (en)
Inventor
Hugh Griffith
Christopher Mcguigan
Magdalena Slusarczyk
Michaela Serpi
Valentina Ferrari
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53499027&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3160978(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1411253.6A external-priority patent/GB201411253D0/en
Application filed by NuCana plc filed Critical NuCana plc
Application granted granted Critical
Publication of DK3160978T3 publication Critical patent/DK3160978T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
DK15733497.0T 2014-06-25 2015-06-25 Gemcitabin-prodrugs DK3160978T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1411253.6A GB201411253D0 (en) 2014-06-25 2014-06-25 Prodrug
IN2050MU2014 2014-06-25
PCT/GB2015/051857 WO2015198058A1 (en) 2014-06-25 2015-06-25 Gemcitabine prodrugs

Publications (1)

Publication Number Publication Date
DK3160978T3 true DK3160978T3 (da) 2020-08-17

Family

ID=53499027

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15733497.0T DK3160978T3 (da) 2014-06-25 2015-06-25 Gemcitabin-prodrugs

Country Status (28)

Country Link
US (2) US10662213B2 (da)
EP (2) EP3757112B1 (da)
JP (2) JP6982957B2 (da)
KR (2) KR102407935B1 (da)
CN (2) CN111214480A (da)
AU (2) AU2015278899B2 (da)
CA (1) CA2945938C (da)
CL (1) CL2016003260A1 (da)
CY (1) CY1123389T1 (da)
DK (1) DK3160978T3 (da)
EA (1) EA034890B1 (da)
ES (2) ES2948660T3 (da)
HR (2) HRP20230584T1 (da)
HU (2) HUE062474T2 (da)
IL (2) IL248642B (da)
LT (1) LT3160978T (da)
ME (1) ME03817B (da)
MX (2) MX2021001140A (da)
MY (1) MY183198A (da)
NZ (2) NZ765508A (da)
PH (1) PH12016502553B1 (da)
PL (1) PL3160978T3 (da)
PT (1) PT3160978T (da)
RS (1) RS60968B1 (da)
SG (2) SG11201608808TA (da)
SI (1) SI3160978T1 (da)
TW (2) TWI758728B (da)
WO (1) WO2015198058A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE044605T2 (hu) 2012-11-16 2019-11-28 Univ College Cardiff Consultants Ltd RP/SP gemcitabin-[fenil-(benziloxi-L-alaninil)]-foszfát keveréke
MX2021001140A (es) 2014-06-25 2022-04-21 Nucana Biomed Ltd Profármacos de gemcitabina.
WO2015198059A1 (en) 2014-06-25 2015-12-30 Nucana Biomed Limited Formulation comprising a gemcitabine-prodrug
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
CN106543220A (zh) 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
CN106478753A (zh) * 2015-09-16 2017-03-08 博瑞生物医药（苏州）股份有限公司 一种nuc‑1031单一异构体的制备方法和用途
CN106543252A (zh) 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
WO2017060661A1 (en) 2015-10-05 2017-04-13 Nucana Biomed Limited Combination therapy
AU2016367237B2 (en) 2015-12-11 2020-12-24 Laurus Labs Limited Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug NUC-1031
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
CN107652342A (zh) * 2016-07-23 2018-02-02 江苏万高药业股份有限公司 核苷氨基磷酸酯类前药的多晶型及其制备方法
CN106946960A (zh) * 2017-03-29 2017-07-14 郑州泰基鸿诺医药股份有限公司 一种吉西他滨前药的晶型、制备方法、用途和药物组合物
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
CN110806454A (zh) * 2018-08-06 2020-02-18 江苏正大清江制药有限公司 一种盐酸吉西他滨中手性异构体的检测方法
CN110215469B (zh) * 2019-07-08 2021-11-30 绍兴市人民医院 一种治疗胆管癌的药物组合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US6069252A (en) 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
BR9907736A (pt) 1998-01-23 2000-10-17 Newbiotics Inc Agentes terapêuticos catalisados por enzima
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
DE60042073D1 (de) 1999-07-22 2009-06-04 Celmed Oncology Usa Inc Enzym katalisierte therapeutische aktivierung
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
US20080096967A1 (en) 2005-01-27 2008-04-24 Erimos Pharmaceuticals Llc Formulations for Injection of Catecholic Butanes, Including Ndga Compounds, Into Animals
EP1928475B1 (en) 2005-08-15 2018-05-23 Riboscience LLC Antiviral phosphoramidates of 4'-c-azido-substituted pronucleotides
JP5528708B2 (ja) 2006-02-09 2014-06-25 参天製薬株式会社 安定な製剤ならびにそれらを調製および使用する方法
GB0821994D0 (en) * 2008-12-02 2009-01-07 Ge Healthcare Ltd In viva imaging method
EA201170915A1 (ru) 2009-01-09 2012-02-28 Юниверсити Колледж Оф Кардифф Консалтентс Лимитед Фосфорамидатные производные гуанозиновых нуклеозидов для лечения вирусных инфекций
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
BR112012011784A2 (pt) 2009-11-20 2019-09-24 Clavis Pharma Asa "formulações parenterais de derivados de gencitabina".
KR20130110170A (ko) 2010-09-22 2013-10-08 앨리오스 바이오파마 인크. 치환된 뉴클레오타이드 유사체
JP5978232B2 (ja) 2011-03-01 2016-08-24 ニューカナー、バイオメッド、リミテッドＮｕｃａｎａ Ｂｉｏｍｅｄ Ｌｉｍｉｔｅｄ がん治療での使用のための５−フルオロ−２’−デオキシウリジンのホスホラミダート誘導体
CA2863500A1 (en) 2012-01-20 2013-07-25 Aratana Therapeutics Nv Eye drop composition
HUE044605T2 (hu) * 2012-11-16 2019-11-28 Univ College Cardiff Consultants Ltd RP/SP gemcitabin-[fenil-(benziloxi-L-alaninil)]-foszfát keveréke
GB2517988A (en) * 2013-09-09 2015-03-11 Redx Pharma Ltd Compounds
ES2927955T3 (es) 2013-09-11 2022-11-14 Univ Emory Composiciones de nucleótidos y nucleósidos y sus usos
WO2015081133A2 (en) 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. Nucleotides for the treatment of liver cancer
WO2015198059A1 (en) 2014-06-25 2015-12-30 Nucana Biomed Limited Formulation comprising a gemcitabine-prodrug
MX2021001140A (es) 2014-06-25 2022-04-21 Nucana Biomed Ltd Profármacos de gemcitabina.
WO2016012781A1 (en) 2014-07-22 2016-01-28 Nucana Biomed Limited Process for the preparation of gemcitabine-[phenyl(benzoxy-l-alaninyl)] phosphate
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
DK3197456T3 (da) 2015-05-14 2018-06-06 NuCana plc Cancerbehandlinger
WO2017060661A1 (en) 2015-10-05 2017-04-13 Nucana Biomed Limited Combination therapy
AU2016367237B2 (en) 2015-12-11 2020-12-24 Laurus Labs Limited Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug NUC-1031
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
ME03677B (me) 2015-12-23 2020-10-20 NuCana plc Kombinovana terapija
KR102566461B1 (ko) 2015-12-23 2023-08-14 뉴카나 피엘씨 조합 요법

Also Published As

Publication number Publication date
NZ765508A (en) 2023-12-22
HUE053240T2 (hu) 2021-06-28
AU2019216626B2 (en) 2020-07-23
IL272724B (en) 2021-06-30
US11629164B2 (en) 2023-04-18
IL272724A (en) 2020-04-30
JP6970236B2 (ja) 2021-11-24
ES2811268T3 (es) 2021-03-11
MX2021001140A (es) 2022-04-21
WO2015198058A1 (en) 2015-12-30
US20170107246A1 (en) 2017-04-20
AU2015278899A1 (en) 2016-11-03
KR20220080220A (ko) 2022-06-14
SG11201608808TA (en) 2016-11-29
US20200262861A1 (en) 2020-08-20
CA2945938A1 (en) 2015-12-30
JP2017519014A (ja) 2017-07-13
LT3160978T (lt) 2020-08-25
MY183198A (en) 2021-02-18
CN111214480A (zh) 2020-06-02
KR102563040B1 (ko) 2023-08-02
TW201613614A (en) 2016-04-16
PH12016502553A1 (en) 2017-04-10
IL248642A0 (en) 2017-01-31
PT3160978T (pt) 2020-08-24
EP3757112A1 (en) 2020-12-30
JP6982957B2 (ja) 2021-12-17
ES2948660T3 (es) 2023-09-15
PH12016502553B1 (en) 2017-04-10
PL3160978T3 (pl) 2020-11-30
EP3757112B1 (en) 2023-06-07
US10662213B2 (en) 2020-05-26
CA2945938C (en) 2023-04-18
NZ725205A (en) 2023-12-22
TWI695718B (zh) 2020-06-11
JP2020152725A (ja) 2020-09-24
CL2016003260A1 (es) 2017-10-06
AU2015278899B2 (en) 2019-07-18
SG10201907898SA (en) 2019-09-27
TW202033204A (zh) 2020-09-16
HRP20230584T1 (hr) 2023-09-15
CN106459129B (zh) 2020-03-31
EA201692312A1 (ru) 2017-04-28
CN106459129A (zh) 2017-02-22
EP3160978B1 (en) 2020-07-29
EA034890B1 (ru) 2020-04-02
EP3757112C0 (en) 2023-06-07
RS60968B1 (sr) 2020-11-30
HUE062474T2 (hu) 2023-11-28
SI3160978T1 (sl) 2020-11-30
KR20170043479A (ko) 2017-04-21
TWI758728B (zh) 2022-03-21
KR102407935B1 (ko) 2022-06-10
MX2016015628A (es) 2017-07-04
ME03817B (me) 2021-04-20
AU2019216626A1 (en) 2019-09-05
EP3160978A1 (en) 2017-05-03
HRP20201264T1 (hr) 2021-02-05
CY1123389T1 (el) 2021-12-31
IL248642B (en) 2020-03-31

Similar Documents

Publication Publication Date Title
DK3135609T3 (da) Artikeltransportanlæg
DK3160978T3 (da) Gemcitabin-prodrugs
DK3110442T3 (da) Modificerede meningokok-fhbp-polypeptider
UA31197S (uk) Таблетка
DK3307076T3 (da) Podepartikelprodukt
ES1119860Y (es) Caramelo
FI10983U1 (fi) Rakennustuote
TH1601003376A (th) ผลิตภัณฑ์ดูดซับ
TH1601002833B (th) ผลิตภัณฑ์ดูดชับ
CL2015001475S1 (es) Estante
CL2015001474S1 (es) Estante
TH1601000408A (th) ผลิตภัณฑ์ดูดซับ
TH1501007868A (th) ผลิตภัณฑ์ดูดซับ
UA28925S (uk) Серветка
UA28928S (uk) Серветка
UA28924S (uk) Серветка
TH1601001888A (th) ผลิตภัณฑ์ซึมซับ
TH1601003049A (th) ผลิตภัณฑ์ซึมซับ
TH1501007129B (th) ผลิตภัณฑ์ซึมซับ
TH1501007352B (th) ผลิตภัณฑ์ซึมซับ
TH1601006627A (th) ผลิตภัณฑ์ซึมซับ
TH1601006581A (th) ผลิตภัณฑ์ซึมซับ
TH1501007718A (th) ผลิตภัณฑ์ซึมซับ
TH1501006414B (th) ผลิตภัณฑ์ซึมซับ
UA30033S (uk) Серветка